Document:

ASSET PURCHASE AGREEMENT

 

THIS ASSET PURCHASE AGREEMENT (“Agreement”) is made
effective September 30, 2011, by and between REDPOINT BIO CORPORATION, a Delaware corporation with its principal executive
offices at 7 Graphics Drive, Ewing, New Jersey 08628 (“Seller”), and OPERTECH BIO, INC., a Delaware corporation
with its principal executive offices at Korman Research Pavilion, Albert Einstein Healthcare Network, 5501 Old York Road, Philadelphia,
PA 19141-3018 (“Buyer”).

 

Seller and Buyer, in consideration of the mutual agreements
and covenants contained herein and subject to the satisfaction of the conditions and occurrence of the contingencies as identified
and set forth herein, and intending to be legally bound hereby, make the following representations and warranties, give the following
covenants, and agree to the purchase and sale of the assets relating to the Seller’s novel strategy to identify substances
that may be effective as taste modulators, including Microtiter Operant Gustometer (MOG) technology (the “Technology”),
generally, and more specifically as follows:

 

Section 1

 

Purchase of Assets

 

		1.1	Subject to the terms and conditions set forth in this Agreement and on the basis of and reliance upon the warranties, representations,
and covenants set forth herein, the Seller agrees to sell, assign, and transfer to the Buyer, and the Buyer agrees to purchase,
at the time of Closing, all of the assets, properties, interest, and rights of the Seller in the Technology (the “Assets”).
In addition, and without limiting the foregoing, the Seller agrees to sell, assign, and transfer to the Buyer, and the Buyer agrees
to purchase the following:

 

		a)	Intellectual Property, consisting of:

 

		i)	Two (2) U.S. patent applications (11/275,059, 12/071,151 and related foreign patent filings/application and all related technology);

 

		ii)	Trade Mark: “We make sense of taste” and all related rights;

 

		iii)	All know-how and trade secrets relating solely to the Technology; and

 

		iv)	All other intellectual property relating solely to the Technology;

 

		b)	Contracts, and all related rights and any work in progress, with:

 

		i)	Merisant (excluding the $25,000 deposit received by the Seller from Merisant); and

 

		ii)	Medisyn Technologies (excluding the $50,000 deposit received by the Seller from Medisyn);

    	 

    	 

    

 

		c)	Customer prospects and related lists, telephone numbers and contacts (and related business development and marketing materials)
relating to the Technology;

 

		d)	Office tenancy at Korman Research Pavillion/Albert Einstein in Philadelphia, including related office telephone numbers;

 

		e)	Equipment, consisting of:

 

		i)	9 MOGs;

		ii)	4 mouse operant chambers;

		iii)	1 Matrix PlateMate 2x3;

		iv)	1 Sartorius balance;

		v)	6 computers, together with all software and data residing thereon (consisting of 2 laptops and 4 desktop work stations);

		vi)	1 HP color laser jet printer;

		vii)	1 HP printer/fax/scanner/copier;

		viii)	4 steel shelving racks;

		ix)	2 stainless steel procedure tables; and

		x)	3 Servers, together with all software and data residing thereon, including Oracle database server (See Section 8.9 below);

 

		f)	Cheminformatics assets, consisting of:

 

		i)	Database for sweet and unami compounds and related files, documents, notebooks and other information resulting from cheminformatics
searches performed by the Seller prior to the Closing; and

 

		ii)	Software, scripts and protocols used to perform cheminformatics operations;

 

		g)	Compounds, consisting of:

 

		(1)	GRAS-like library, consisting of ~9,000 compounds;

		(2)	Natural product library, comprised of compounds from IBS and Analyticon, consisting of ~400 compounds;

 

		h)	Any inventory of supplies relating solely to the Technology;

 

		i)	Documents, files and records containing technical support and other information relating to the operation of the Technology;

 

		j)	All other properties (tangible and intangible), assets and information necessary or used solely to conduct the Technology.

 

		1.2	The following assets, among others, of the Seller and the Business shall be excluded from this Agreement, and shall not be
assigned or transferred to Buyer:

    	 

    	 

    

 

		a)	Redpoint Bio screening library (~230K compounds including Blanca, Preswick, and LifeChem libraries);

		b)	Redpoint Bio files not relating solely to the Assets or Assumed Liabilities;

		c)	Synthesized compounds from TRPM5 lead optimization (~1,500 compounds);

		d)	2 large glass-front lab cabinets;

		e)	Laboratory glassware; and

		f)	1 vacuum pump.

  

Section 2

 

Liabilities

 

		2.1	As of Closing, except as set forth in Section 2.2, Buyer does not and shall not assume or be responsible for any liabilities,
debts, or other obligations of the Seller.

 

		2.2	As additional consideration for the purchase of the Assets, Buyer shall assume only the following specified liabilities (the
“Assumed Liabilities”):

 

		a)	Office lease obligations (month to month) at Korman Research Pavillion/Albert Einstein in Philadelphia from and after the date
of the Closing;

 

		b)	Performance obligations specified in the contracts with Merisant and Medisyn Technologies relating to the Assets arising after
the Closing; and

 

		c)	Liabilities and obligations arising in connection with the use of the Assets by Buyer after the Closing.

 

		2.3	Notwithstanding any provision in this Agreement or any other writing to the contrary, neither Buyer nor any of its affiliates
is assuming any liability or obligation of Seller (or any predecessor of Seller or any prior owner of all or part of its businesses
or assets) of whatever nature, whether presently in existence or arising hereafter, other than the Assumed Liabilities.  All
such liabilities and obligations shall be retained by and remain obligations and liabilities of Seller (all such liabilities and
obligations not being assumed being herein referred to as the “Excluded Liabilities”).  Notwithstanding any provision
in this Agreement or any other writing to the contrary and without limiting the generality of the term “Excluded Liabilities”,
the Excluded Liabilities shall include:

 

		a)	all liabilities and obligations of Seller, or any member of any consolidated, affiliated, combined or unitary group of which
Seller is or has been a member for taxes or other charges;

    	 

    	 

    

 

		b)	all liabilities and obligations relating to employee benefits or compensation arrangements in relation to Seller or its business,
whether relating or attributable to, or arising during, the period before or after Closing, including all liabilities or obligations
under any employee benefit agreements, retention, severance or other plans or other arrangements;

 

		c)	all liabilities and obligations arising from any action relating to Seller, its business or the Assets pending before any tribunal,
arbitrator or governmental authority;

 

		d)	all liabilities and obligations relating to or arising from any presently or formerly owned, operated or leased asset, property
or business of Seller that is not an Asset being acquired by Buyer pursuant to this Agreement, whether relating or attributable
to, or arising during, the period before or after Closing; and

 

		e)	all liabilities and obligations relating or attributable to, or arising during, the operation of the Seller’s business
and any owned, leased or operated Asset prior to Closing, including in relation to any contract (including any assumed Contract),
agreement, lease, license, commitment, sales or purchase order or other instrument.

 

Section 3

 

Purchase Price

 

		3.1	Purchase Price.

 

		a)	The purchase price payable by Buyer to Seller shall be the sum of TWENTY SEVEN THOUSAND FIVE HUNDRED DOLLARS ($27,500.00) (the
“Closing Payment”) paid by check or wire transfer of immediately available funds at the Closing.

 

		b)	If, during the one (1) year following the Closing, Buyer is sold, or the Buyer sells substantially all of the Technology, to
an independent third party for proceeds greater than an amount equal to the sum of (i) the Closing Payment; plus (ii) all capital
invested in Buyer by its stockholders as of the date of such sale (the “Invested Capital”), then Buyer shall, within
ten (10) days following the completion of such sale transaction, pay to Seller as additional purchase price for the Assets an amount
equal to ten percent (10%) of the net proceeds from such sale transaction (with “net proceeds” defined for this purpose
as gross proceeds received by the Buyer for a sale of assets or its stockholders for a sale of stock, less all transaction expenses,
taxes and the Invested Capital). If no such sale transaction has occurred within such one (1) year period, Buyer shall have no
obligations to Seller under this Section.

 

		3.2	Transfer Taxes. Seller shall be liable for and shall pay all applicable federal, state and local taxes and other like
charges properly payable on and in connection with the conveyance and transfer of the Assets to Buyer. Buyer will do and cause
to be done such things as are reasonably requested to enable Seller to comply with such obligation in an efficient manner.

    	 

    	 

    

 

		3.3	Bulk Sales.  Buyer hereby waives compliance by Seller with the provisions of any and all laws relating to bulk
transfers in connection with the sale of the Assets. Seller covenants and agrees to indemnify and save harmless Buyer from and
against any and all losses, liability, cost and expense (including reasonable attorney's fees) arising out of noncompliance with
such bulk transfers laws.

 

Section 4

 

Closing

 

		4.1	The closing (the “Closing”) will take place on September 30, 2011 at the offices of the Buyer at a date and time
as mutually agreed upon by Buyer and Seller. The Seller agrees to execute any and all documents necessary to effectuate the terms
of this Agreement. Each of the parties hereto agrees to use all commercially reasonable efforts to take, or cause to be taken,
all action, and to do, or cause to be done, all things necessary, proper or advisable to the extent permissible under applicable
law, to consummate and make effective the transactions contemplated by this Agreement as expeditiously as practicable and to ensure
that the conditions set forth in this Agreement are satisfied, insofar as such matters are within the control of such party. Title
to the Assets shall pass from Seller to Buyer upon the Closing.

 

		4.2	Buyer’s Deliveries. At the Closing, Buyer shall deliver or cause to be delivered to Seller the Closing Payment.

 

		4.3	Seller’s Deliveries. At the Closing, Seller shall deliver or cause to be delivered to Buyer the following:

 

		(a)	An executed Bill of Sale, in substantially the form attached hereto as Exhibit A (the “Bill of Sale”);

 

		(b)	Physical possession of the offices at Korman Research Pavillion/Albert Einstein in Philadelphia; and

 

		(c)	Copies of each assumed contract, and physical possession of any tangible Assets, together with such other instruments as may
be reasonably requested by Buyer to vest in Buyer good and marketable title to all of the Assets.

 

    	 

    	 

    

 

Section 5

 

Representations and Warranties

 

		5.1	Seller represents and warrants to Buyer as Follows:

 

		a)	Seller is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation,
and has all requisite corporate power and authority to own the Assets, to execute and deliver this Agreement, to consummate the
transactions contemplated hereby and to perform all the terms and conditions hereof to be performed by it.

 

		b)	Seller has taken all necessary corporate action to authorize the execution and delivery of this Agreement, the performance
by it of all terms and conditions hereof to be performed by it and the consummation of the transactions contemplated hereby. This
Agreement constitutes the legal, valid and binding obligations of Seller, enforceable in accordance with its terms.

 

		c)	The execution, delivery and performance by Seller of this Agreement, and the consummation of the transactions contemplated
hereby will not (with or without the giving of notice or the lapse of time, or both) (i) violate any provision of the charter or
bylaws of Seller, (ii) violate, or require any consent, authorization or approval of, or exemption by, or filing under any provision
of any law, statute, rule or regulation to which Seller or the Assets are subject, (iii) violate any judgment, order, writ or decree
of any court applicable to Seller or the Assets, (iv) conflict with, result in a breach of, constitute a default under, or accelerate
or permit the acceleration of the performance required by, or require any consent, authorization or approval under any contract,
agreement or instrument to which Seller is a party or any of the Assets is bound or (v) result in the creation or imposition of
any lien or other encumbrance upon the Assets, which violation, conflict, breach, default, acceleration or lien or other encumbrance,
or the failure to make or obtain such filing, consent, authorization or approval, with respect to the matters specified in clauses
(ii) through (v) could, individually or in the aggregate, reasonably be expected to have a material adverse effect on any of the
Assets or prevent or delay the consummation of the transactions contemplated by this Agreement.

 

		d)	Seller has good and marketable title to, or valid contract rights to, as applicable, all of the Assets free and clear of all
liens or other encumbrances, and has the power and right to sell, convey, deliver, transfer and assign to Buyer, as applicable,
the Assets. There are no adverse claims of ownership to the Assets. No Person has asserted a claim of ownership or right of possession
or use in or to any of the Assets.  At the Closing, Seller will transfer to Buyer, good and marketable title to, or valid
contract rights to, as applicable, all of the Assets, free and clear of all liens or other encumbrances.

 

    	 

    	 

    

 

		e)	Seller has timely paid all taxes and other charges that will have been required to be paid by it in respect of its business
and the Assets, the non-payment of which would result in a lien or other encumbrance on any Asset, would otherwise adversely affect
the Assets or would result in Buyer becoming liable or responsible for such taxes and other charges.

 

		f)	Except for pending litigation involving the Seller’s landlord with respect to its former New Jersey headquarters office,
there are no writs, injunctions, decrees, orders or judgments outstanding against Seller and no written notice, notification, demand,
request for information, citation, summons or order has been received by Seller, no written complaint has been filed, no penalty
has been assessed and no investigation, action, claim, suit or proceeding is pending, or to Seller’s knowledge, threatened
by any governmental authority or other person involving any of Seller, any current or former subsidiary of Seller or the current
or past activities, operations, real property or assets of Seller or any current or former subsidiary of Seller and relating to
or arising out of any environmental law or hazardous substance against Seller, (i) which remains unresolved; and (iii) alleges
or is with respect to a violation of any applicable environmental law.

 

		g)	Until the time of closing, Seller will use commercially reasonable efforts to preserve and maintain the course and shall not
enter into any contract or transaction with third parties not in the ordinary course of business, and not without the written consent
of Buyer.

 

		h)	Seller has not incurred any liability for broker’s, finder’s, agent’s fees or commissions and/or similar
forms of compensation in connection with this Agreement or the transactions contemplated by it.

 

		i)	All tangible assets and properties which are part of the Assets are in good operating condition and repair and are usable in
the ordinary course consistent with past practice and conform in all material respects to all applicable laws and regulations relating
to their construction, use and operation.

 

		j)	As to all intellectual property constituting part of the Assets, Seller has delivered or made available to Buyer correct and
complete copies of all documentation related thereto. To the knowledge of Seller, use by Seller of such intellectual property does
not infringe any rights of any third party and no activity of any third party infringes upon the rights of Seller with respect
to any of such intellectual property. Seller has not granted to any person any interest in such intellectual property by license,
sublicense, contract, assignment, or otherwise.

 

    	 

    	 

    

 

		k)	There is no action pending, or to Seller’s knowledge, threatened before any tribunal or other governmental authority,
and there is no claim, investigation or administrative action of any governmental authority pending, or to Seller’s knowledge,
threatened, that, either individually or in the aggregate, could reasonably be expected to have a material adverse effect on the
Seller or the Assets. 

 

		l)	Other that this Agreement, there are no pending contracts or agreements for the sale or purchase of the Assets.

  

		5.2	Buyer’s Representations. Buyer represents, warrants and covenants to Seller as follows:

 

		a)	Buyer is a limited liability company duly organized and validly subsisting under the laws of the Commonwealth of Pennsylvania
and has the power and authority to enter into this Agreement and to carry out and perform its obligations;

 

		b)	This Agreement has been duly authorized, executed and delivered by, and is enforceable against Buyer; and

 

		c)	There are no claims, actions, suits, litigation, labor disputes, arbitrations, proceedings or investigations pending or, to
the best knowledge of Buyer, threatened against Buyer relating to the transactions contemplated by this Agreement.

 

		5.3	Seller’s and Buyer’s warranties and representations will survive the closing for a period of three (3) months.

  

Section 6

 

Conditions and Contingencies to Buyer’s
obligations

 

		6.1	The obligations of the Buyer are specifically subject to the following conditions and contingencies, all of which must occur
and/or be satisfied as of the closing:

    	 

    	 

    

 

		a)	There shall have been no breach by Seller in the performance of any of its covenants herein, and each of the representations
and warranties of the Seller contained or referred to in this Agreement shall be true and correct in all material respects as of
the Closing;

 

		b)	The properties and assets of Seller shall not have been damaged or impaired, so as to impair in any materially adverse respect
the ability of Buyer to continue the use of the Assets in the ordinary course;

 

		c)	Seller shall make available to Buyer, and Buyer shall have the right to review and inspect to its satisfaction, any and all
financial information relative to the Seller and/or the Assets, any and all of Seller’s ownership, organizational or title
documents relating to the Assets, and/or any of the Seller’s agreements or contracts with third parties.

 

		d)	No applicable law or judicial or governmental order shall have been enacted, entered, promulgated or enforced by any governmental
authority that prohibits the consummation of all or any part of the transactions contemplated by this Agreement, and no action
shall be pending or threatened by any governmental authority or other person seeking any such order or decree or seeking to recover
any damages or obtain other relief as a result of the consummation of such transactions.

 

		e)	Buyer shall have received a certificate, dated as of the Closing Date, duly executed by an authorized officer of Seller, certifying
that all of the conditions set forth above have been satisfied; the resolutions adopted by the Board of Directors of Seller
authorizing the execution, delivery and performance of this Agreement, as attached to the certificate, were duly adopted, remain
in full force and effect, and have not been amended, rescinded or modified; and Seller’s officer executing this Agreement,
and each of the other documents necessary for consummation of the transactions contemplated herein, is an incumbent officer, and
the specimen signature on such certificate is a genuine signature.

 

		f)	Buyer shall have received a certificate of good standing in respect of Seller certified by the Secretary of State or other
appropriate official of the State of Delaware, dated as of a date not more than five (5) days prior to the Closing Date.

 

		g)	Buyer shall have received such other documents, agreements and instruments as it may reasonably request in connection with
the consummation of the transactions contemplated hereby.

    	 

    	 

    

 

Section 7

 

Employee Matters; Post-Closing Matters

 

		8.1	Offer of Employment. Buyer shall offer employment on and as of the Closing Date, on an at-will basis, to Scott Horvitz,
Kyle Palmer, Tulu Buber and Daniel Long (the “Employees”) in substantially similar jobs as were provided by Seller
immediately prior to the Closing Date. Notwithstanding the foregoing, Buyer shall make available to Seller Scott Horvitz on a limited
part time basis for certain close out activities, at mutually agreed compensation, pursuant to a consulting agreement between Seller
and Scott Horvitz to be entered into on the Closing Date or within fifteen (15) days thereafter.

  

		8.2	Transition of Employees. From and after the Closing Date, Seller shall cooperate to ensure an orderly transition of
the Employees who accept employment with Buyer.

 

		8.3	Other Employee Benefits. Seller agrees that, with respect to claims for workers' compensation and all claims under Seller's
employee benefit programs by persons working for the Seller arising out of events occurring prior to the Closing, whether reported
or unreported as of the Closing and whether insured or uninsured (including, but not limited to, workers' compensation, life insurance,
medical and disability programs), Seller shall, at its own expense, honor or cause its insurance carriers to honor such claims
in accordance with the terms and conditions of such programs or applicable workers' compensation statutes. Without limiting the
scope of the preceding sentence, Seller shall be responsible for any and all claims and liabilities arising out of or relating
to (i) its employment of the Employees, (ii) the termination by Seller of such employment of any such Employee and (iii) the provision
of any employee benefits to such Employees (and their beneficiaries and eligible dependents) attributable to their employment with,
or their participation in any plans or programs maintained or contributed to by, Seller or any of its affiliates.

 

		8.4	Covenant Not to Interfere. Both Seller and Buyer hereby covenant and agree that, unless this Agreement is terminated,
for a period of five years after the Closing Date, they will not, whether for their own account or for the account of any other
person, endeavor to entice away from the other party any person who is an employee of such party other than as contemplated by
this Agreement.

 

		8.5	Administrative Assistance by Seller. Except as otherwise agreed, Seller shall provide such accounting, data processing
and other support services to Buyer as are reasonably required in connection with the transfer of the Assets to Buyer without cost
to Buyer for a period of not more than 60 days following the Closing Date.

 

    	 

    	 

    

		8.6	Further Assurances of Seller. From and after the Closing Date, Seller shall, at the request of Buyer, execute, acknowledge
and deliver to Buyer, without further consideration, all such further assignments, conveyances, endorsements, deeds, special powers
of attorney, consents and other documents, and take such other action, as Buyer may reasonably request (i) to transfer to and vest
in Buyer, and protect its rights, title and interest in, all the Assets and (ii) otherwise to consummate the transactions contemplated
by this Agreement. In addition, from and after the Closing Date, Seller shall afford Buyer and its attorneys, accountants and other
representatives access, during normal business hours, to any books and records relating to the Assets that Seller may retain as
may reasonably be required in connection with the preparation of financial information or tax returns of Buyer.

 

		8.7	Confidentiality. From and after the Closing Date, Seller agrees to hold in strictest confidence, and not to use or to
disclose to any person without written authorization of Buyer, all information pertaining to the Assets that is not generally available
to the public, including research, plans, products, services, customer lists and customers, markets, developments, inventions,
processes, marketing, finances or other business information.

 

		8.8	Shared Data Processing Resources. From and after the Closing for a period of not more than one (1) year, Buyer shall
permit Seller to continue to use, at no charge to Seller, an Oracle database server.

 

		8.9	Storage of Assets Not Acquired. From and after the Closing for a period of not more than one (1) year, Buyer shall store
certain assets of the Seller that are not included in the Assets being acquired by Buyer pursuant to this Agreement, at no charge
to the Seller, consisting of:

 

		a)	Redpoint Bio screening library (~230K compounds including Blanca, Preswick, and LifeChem libraries);

		b)	Redpoint Bio files not relating to the Assets or Assumed Liabilities;

		c)	Synthesized compounds from TRPM5 lead optimization (~1,500 compounds);

		d)	2 large glass-front lab cabinets;

		e)	Laboratory glassware; and

		f)	1 vacuum pump.

 

Section 9

 

Miscellaneous Items

 

		9.1	If a dispute arises, the prevailing party in any resulting litigation proceeding shall be entitled to an amount from the other
party equal to the costs, expenses and fees incurred, including attorneys’ fees, by the prevailing party from such litigation.

 

		9.2	This is the entire agreement between the parties. It replaces and supersedes any and all oral agreements between the parties,
as well as any prior writings.

 

		9.3	This agreement binds and benefits the successors and assignees of the parties.

 

    	 

    	 

    

		9.4	All notices hereunder must be in writing. A notice may be delivered to a party at the address set forth above or to a new address
that a party later designates in writing. Notice may be delivered in person, by certified mail, or by overnight courier.

 

		9.5	This agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without reference
to its conflict of law provisions. The parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of
the federal and state courts located within the Commonwealth of Pennsylvania for any action arising out of or relating to this
Agreement and the transactions contemplated hereby. The parties further hereby irrevocably and unconditionally waive any objection
to the laying of venue of any action arising out of or relating to this Agreement or the transactions contemplated hereby in such,
and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action
brought in any such court has been brought in an inconvenient forum. Each party hereto further agrees that service of any process,
summons, notice or document by U.S. registered mail to its address set forth below shall be effective service of process for any
action brought against it under this Agreement in any such court. EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT TO
TRIAL BY JURY WITH RESPECT TO ANY ACTION RELATING TO OR ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREIN.

 

		9.6	The parties may sign several identical counterparts of this Agreement. Any fully signed counterpart shall be treated as an
original.

 

		9.7	This Agreement may be modified only by a writing signed by both parties.

 

		9.8	If any court determines that any provision of this agreement is invalid or unenforceable, any invalidity or unenforceability
will affect only that provision and will not make any other provision of this agreement invalid or unenforceable and such provision
shall be modified, amended or limited only to the extent necessary to render it valid and enforceable.

 

		9.9	The parties shall each bear their own expenses, including legal fees, incurred in connection with this Agreement and the contemplated
transactions.

 

		9.10	Each of the parties hereto will duly comply with all applicable laws to complete validly the transactions provided for in this
Agreement.

 

		9.11	The parties shall take any actions and execute any other documents that may be necessary or desirable to the implementation
and consummation of this Agreement, including, in the case of Seller, any additional transfer documents that, in the reasonable
opinion of Buyer, may be necessary to ensure, complete, and evidence the full and effective transfer of the Assets to Buyer pursuant
to this Agreement. Seller will cooperate with Buyer, after the Closing Date, in the preparation of tax returns and any other required
filings.

    	 

    	 

    

 

		9.12	Neither of the parties shall issue nor permit any of its affiliates to issue any press release or other public announcement
with respect to this Agreement or the transactions contemplated hereby without the prior consent of the other party.

 

IT IS SO AGREED BY AND BETWEEN THE BUYER AND SELLER:

 

	SELLER:  REDPOINT BIO CORPORATION
	 
	BY:	/s/
    Scott Horvitz	 
	Name:	Scott Horvitz	 
	Title:	Chief
    Financial Officer	 
	 	 	 
	BUYER:  OPERTECH BIO, INC.
	 
	By:	/s/ Irwin Scher	 
	 	Irwin Scher, President	 

 

 

    	 

    	 

    

 

BILL OF SALE 

 

KNOW ALL MEN BY THESE PRESENTS, that, REDPOINT BIO CORPORATION,
a Delaware corporation (the “Seller”), in consideration of good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, paid by Opertech Bio, Inc., a Delaware corporation (the “Buyer”), and intending to
be legally bound, hereby sells, conveys, delivers, assigns and transfers to the Buyer, pursuant to and in furtherance of the Asset
Purchase Agreement dated as of September 30, 2011 (the “Agreement”) by and between the Seller and the Buyer all right,
title and interest of the Seller in and to, among other items set forth in the Agreement, the assets listed in the Schedule A attached.
All capitalized terms used herein without definition shall have the respective meanings ascribed to them in the Agreement.

 

This Bill of Sale is being executed and delivered as a condition
to the Agreement and is expressly hereby made subject to and shall have the benefits of the respective representations, warranties,
covenants, terms, conditions, limitation and other provisions of the Agreement.

 

The Seller further covenants and agrees that it shall execute
such other and further instruments and documents as the Buyer may reasonably request to carry into effect or to evidence further
the transfer of the Assets of the Seller to the Buyer.

 

TO HAVE AND TO HOLD the same unto the Buyer, its successors
and assigns for its and their own use and benefit forever.

 

IN WITNESS WHEREOF, the Seller has executed this instrument
as of the Closing Date of September 30, 2011.

 

	REDPOINT BIO CORPORATION	 
	 	 
	By:	 	 
	Name:	 
	Title:	 

 

    	 

    	 

    

  

Schedule A to Bill of Sale

 

All of the assets, properties, interest, and rights of the Seller
in the Seller’s novel strategy to identify substances that may be effective as taste modulators, including Microtiter Operant
Gustometer (MOG) technology (the “Technology”). In addition, and without limiting the foregoing, the Seller agrees
to sell, assign, and transfer to the Buyer, and the Buyer agrees to purchase the following (the “Assets”):

 

		a)	Intellectual Property, consisting of:

 

		i)	Two (2) U.S. patent applications (11/275,059, 12/071,151 and related foreign patent filings/application and all related technology;

 

		ii)	Trade Mark: “We make sense of taste” and all related rights;

 

		iii)	All know-how and trade secrets relating to the Technology; and

 

		iv)	All other intellectual property relating to the Technology;

 

		b)	Contracts, and all related rights and any work in progress, with:

 

		i)	Merisant (excluding the $25,000 deposit received by the Seller from Merisant); and

 

		ii)	Medisyn Technologies (excluding the $50,000 deposit recently received by the Seller from Medisyn);

 

		c)	Customer prospects and related lists, telephone numbers and contacts (and related business development and marketing materials)
relating to the Technology;

 

		d)	Office tenancy at Korman Research Pavillion/Albert Einstein in Philadelphia (subject to review of lease documents), including
related office telephone numbers;

 

		e)	Equipment, consisting of:

 

		i)	9 MOGs;

		ii)	4 mouse operant chambers;

		iii)	1 Matrix PlateMate 2x3;

		iv)	1 Sartorius balance;

		v)	6 computers, together with all software and data residing thereon (consisting of 2 laptops and 4 desktop work stations);

		vi)	1 HP color laser jet printer;

    	 

    	 

    

		vii)	1 HP printer/fax/scanner/copier;

		viii)	4 steel shelving racks;

		ix)	2 stainless steel procedure tables; and

		x)	3 Servers, together with all software and data residing thereon, including Oracle database server;

 

		f)	Cheminformatics assets, consisting of:

 

		i)	Database for sweet and unami compounds and related files, documents, notebooks and other information resulting from cheminformatics
searches performed by the Seller prior to the Closing; and

 

		ii)	Software, scripts and protocols used to perform cheminformatics operations;

 

		g)	Compounds, consisting of:

 

		(1)	GRAS-like library, consisting of ~9,000 compounds;

		(2)	Natural product library, comprised of compounds from IBS and Analyticon, consisting of ~400 compounds;

 

		h)	Any inventory of supplies relating to the Technology;

 

		i)	Documents, files and records containing technical support and other information relating to the operation of the Technology;

 

		j)	All other properties (tangible and intangible), assets and information necessary or used to conduct the Technology.THIS WARRANT AND THE COMMON SHARES ISSUABLE
UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON
SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO MIMVI,
Inc. THAT SUCH REGISTRATION IS NOT REQUIRED.

 

	 	Right to Purchase 2,500,000 shares of Common Stock of MIMVI, Inc. (subject to adjustment as provided herein)

 

COMMON STOCK PURCHASE WARRANT

 

	No. 2010-1	Issue Date: February __, 2012

 

MIMVI, INC., a corporation organized under
the laws of the State of Nevada (the “Company”), hereby certifies that, for value received, Capital Group Communications,
Inc., or its assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company
at any time after the Issue Date until 5:00 p.m., C.S.T on the tenth anniversary after the Issue Date (the “Expiration Date”),
up to 2,500,000 fully paid and nonassessable shares of the Common Stock of the Company (the “Warrant Shares”), at a
per share purchase price of $0.10 in lawful money of the United States. The afore described purchase price per share, as adjusted
from time to time as herein provided, is referred to herein as the “Purchase Price.” The number and character of such
shares of Common Stock and the Purchase Price are subject to adjustment as provided herein. The Company may reduce the Purchase
Price without the consent of the Holder.

 

As used herein the following
terms, unless the context otherwise requires, have the following respective meanings:

 

(a)The term “Company”
shall include MIMVI, Inc. and any corporation which shall succeed or assume the obligations of MIMVI, Inc. hereunder.

 

(b)The term “Common
Stock” includes (a) the Company’s Common Stock, $.001 par value per share, as authorized on the Issue Date, and
(b) any other securities into which or for which any of the securities described in (a) may be converted or exchanged pursuant
to a plan of recapitalization, reorganization, merger, sale of assets or otherwise.

 

(c)The term “Other
Securities” refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate
or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received, on the exercise
of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in
exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise.

 

    	1

    	 

    
 

1.Exercise of Warrant.

 

1.1.Number of Shares
Issuable upon Exercise. From and after the Issue Date through and including the Expiration Date, the Holder hereof shall be
entitled to receive, upon exercise of this Warrant in whole in accordance with the terms of subsection 1.2 or upon exercise
of this Warrant in part in accordance with subsection 1.3, shares of Common Stock of the Company, subject to adjustment pursuant
to Section 4.

 

1.2.Full Exercise.
This Warrant may be exercised in full by the Holder hereof by delivery of an original or facsimile copy of the form of subscription
attached as Exhibit A hereto (the “Subscription Form”) duly executed by such Holder and surrender of the original
Warrant within five (5) trading days of exercise, to the Company at its principal office, accompanied by payment, in cash, wire
transfer or by certified or official bank check payable to the order of the Company, in the amount obtained by multiplying the
number of shares of Common Stock for which this Warrant is then exercisable by the Purchase Price then in effect.

 

1.3.Partial Exercise.
This Warrant may be exercised in part (but not for a fractional share) by surrender of this Warrant in the manner and at the place
provided in subsection 1.2 except that the amount payable by the Holder on such partial exercise shall be the amount obtained
by multiplying (a) the number of whole shares of Common Stock designated by the Holder in the Subscription Form by (b) the
Purchase Price then in effect. On any such partial exercise, the Company, at its expense, will forthwith issue and deliver to or
upon the order of the Holder hereof a new Warrant of like tenor, in the name of the Holder hereof or as such Holder (upon payment
by such Holder of any applicable transfer taxes) may request, the whole number of shares of Common Stock for which such Warrant
may still be exercised.

 

1.4.Fair Market Value.
Fair Market Value of a share of Common Stock as of a particular date (the “Determination Date”) shall mean:

 

(a)If the Company’s
Common Stock is traded on an exchange or is quoted on the National Association of Securities Dealers, Inc. Automated Quotation
(“NASDAQ”), National Market System, the NASDAQ SmallCap Market or the American Stock Exchange, LLC, then the closing
or last sale price, respectively, reported for the last business day immediately preceding the Determination Date;

 

(b)If the Company’s
Common Stock is not traded on an exchange or on the NASDAQ National Market System, the NASDAQ SmallCap Market or the American Stock
Exchange, Inc., but is traded in the over-the-counter market, then the average of the closing bid and ask prices reported for the
last business day immediately preceding the Determination Date;

 

(c)Except as provided
in clause (d) below, if the Company’s Common Stock is not publicly traded, then as the Board of Directors of the Company
shall in good faith determine; or

 

(d)If the Determination
Date is the date of a liquidation, dissolution or winding up, or any event deemed to be a liquidation, dissolution or winding up
pursuant to the Company’s charter, then all amounts to be payable per share to holders of the Common Stock pursuant to the
charter in the event of such liquidation, dissolution or winding up, plus all other amounts to be payable per share in respect
of the Common Stock in liquidation under the charter, assuming for the purposes of this clause (d) that all of the shares
of Common Stock then issuable upon exercise of all of the Warrants are outstanding at the Determination Date.

 

    	2

    	 

    
 

1.5.Delivery of Stock
Certificates, etc. on Exercise. As soon as practicable after the exercise of this Warrant in full or in part, and in any event
within five (5) trading days thereafter, the Company at its expense will cause to be issued in the name of and delivered to the
Holder hereof, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable
securities laws, a certificate or certificates for the number of duly and validly issued, fully paid and nonassessable shares of
Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise, plus, in lieu of any fractional share
to which such Holder would otherwise be entitled, cash equal to such fraction multiplied by the then Fair Market Value of one full
share of Common Stock, together with any other stock or other securities and property (including cash, where applicable) to which
such Holder is entitled upon such exercise pursuant to Section 1 or otherwise.

 

1.6.Common Stock
Legend. The Holder acknowledges and agrees that the shares of Common Stock of the Company, and, until such time as the Common
Stock has been registered under the 1933 Act and sold in accordance with an effective registration statement, or exemption from
registration, certificates and other instruments representing any of the Common Stock shall bear a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of any such Securities):

 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR APPLICABLE STATE SECURITIES LAWS. THESE SHARES MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR ANY
APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO MIMVI,
Inc. THAT SUCH REGISTRATION IS NOT REQUIRED.”

 

1.7Exercise Limitation. Notwithstanding anything
contained herein to the contrary, the Holder shall not be entitled to exercise pursuant to the terms of this Warrant nor may this
Warrant be converted in whole or in part into an amount of Common Stock that would be exercisable into that number of Common Stock
which would exceed the difference between the number of shares of Common Stock beneficially owned by such Holder and 9.99% of the
outstanding shares of Common Stock of the Company. For the purposes of the immediately preceding sentence, beneficial ownership
shall be determined in accordance with Section 13(d) of the Exchange Act and Regulation 13d-3 thereunder. The foregoing limitation
shall be calculated as of each Exercise Date. Aggregate conversions over time shall not be limited to 9.99%. The Holder may void
the Exercise Share limitation described in this Section 1.7 upon 61 days prior notice to the Company. The Holder may allocate which
of the equity of the Company deemed beneficially owned by the Holder shall be included in the 9.99% amount described above and
which shall be allocated to the excess above 9.99%.

 

2.Cashless Exercise.
If the Fair Market Value of one share of Common Stock is greater than the Purchase Price (at the date of calculation as set forth
below), in lieu of exercising this Warrant for cash, the holder may elect to receive shares equal to the value (as determined below)
of this Warrant (or the portion thereof being cancelled) by surrender of this Warrant at the principal office of the Company together
with the properly endorsed Subscription Form in which event the Company shall issue to the holder a number of shares of Common
Stock computed using the following formula:

 

X = Y (A-B)

            A

 

    	3

    	 

    
 

WhereX=the number of shares of
Common Stock to be issued to the holder

 

		Y=	the number of shares of Common Stock purchasable under
the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised (at the date of
such calculation)

		A=	the Fair Market Value of one share of the Company’s
Common Stock (at the date of such calculation)

		B=	Purchase Price (as adjusted to the date of such calculation)

3.Adjustment for
Reorganization, Consolidation, Merger, etc.

 

3.1.Reorganization,
Consolidation, Merger, etc. In case at any time or from time to time, the Company shall (a) effect a reorganization, (b) consolidate
with or merge into any other person or (c) transfer all or substantially all of its properties or assets to any other person
under any plan or arrangement contemplating the dissolution of the Company, then, in each such case, as a condition to the consummation
of such a transaction, proper and adequate provision shall be made by the Company whereby the Holder of this Warrant, on the exercise
hereof as provided in Section 1, at any time after the consummation of such reorganization, consolidation or merger or the
effective date of such dissolution, as the case may be, shall receive, in lieu of the Common Stock (or Other Securities) issuable
on such exercise prior to such consummation or such effective date, the stock and other securities and property (including cash)
to which such Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be,
if such Holder had so exercised this Warrant, immediately prior thereto, all subject to further adjustment thereafter as provided
in Section 4.3.2.

 

3.2Extraordinary
Events Regarding Common Stock. In the event that the Company shall (a) issue additional shares of the Common Stock as
a dividend or other distribution on outstanding Common Stock, (b) subdivide its outstanding shares of Common Stock, or (c) combine
its outstanding shares of the Common Stock into a smaller number of shares of the Common Stock, then, in each such event, the Purchase
Price shall, simultaneously with the happening of such event, be adjusted by multiplying the then Purchase Price by a fraction,
the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator
of which shall be the number of shares of Common Stock outstanding immediately after such event, and the product so obtained shall
thereafter be the Purchase Price then in effect. The Purchase Price, as so adjusted, shall be readjusted in the same manner upon
the happening of any successive event or events described herein in this Section 4. The number of shares of Common Stock that
the Holder of this Warrant shall thereafter, on the exercise hereof as provided in Section 1, be entitled to receive shall
be adjusted to a number determined by multiplying the number of shares of Common Stock that would otherwise (but for the provisions
of this Section 4) be issuable on such exercise by a fraction of which (a) the numerator is the Purchase Price that would
otherwise (but for the provisions of this Section 4) be in effect, and (b) the denominator is the Purchase Price in effect
on the date of such exercise.

 

3.3Anti-Dilution.
If at any time or from time to time after the date of this Warrant, the Company shall issue (or become obligated to issue) shares
of its Common Stock for a price per share less than $0.25 pursuant to a Qualified Financing, the number of Warrant Shares exercisable
shall be adjusted, as of the close of business on the date of the issuance or sale, to an amount sufficient to maintain the Holder’s
Percentage Interest. For purposes of this Section 3.3, a “Qualified Financing” shall mean a sale by the Company of
Common Stock, or debt or equity securities convertible into Common Stock, principally for financing purposes in which cash is received
by the Company or any successor, which shall not include the issuance of options, warrants and other rights to acquire shares of
the Company’s Common Stock to employees, officers or directors of, or contractors, consultants or advisers to, the Company.
For purposes of this Section 4.2, the Holder’s Percentage Interest shall mean the Holder’s percentage interest in the
number of shares of the Company’s issued and outstanding Common Stock on a fully-diluted basis as of the date of this Agreement.
Notwithstanding the foregoing, if pursuant to a Qualified Financing the Company issues debt which is convertible into shares of
the Company’s Common Stock (the “Conversion Shares”), the number of Warrant Shares exercisable pursuant to this
Agreement shall not be adjusted unless and until such time as the Company becomes obligated to issue the Conversion Shares.

  

    	4

    	 

    

 

3.4.Certificate as
to Adjustments. In each case of any adjustment or readjustment in the shares of Common Stock (or Other Securities) issuable
on the exercise of the Warrants, the Company at its expense will promptly cause its Chief Financial Officer or other appropriate
designee to compute such adjustment or readjustment in accordance with the terms of the Warrant and prepare a certificate setting
forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including
a statement of (a) the consideration received or receivable by the Company for any additional shares of Common Stock (or Other
Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or Other Securities)
outstanding or deemed to be outstanding, and (c) the Purchase Price and the number of shares of Common Stock to be received
upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as
provided in this Warrant. The Company will forthwith mail a copy of each such certificate to the Holder of the Warrant.

 

4.Reservation of
Stock, etc. Issuable on Exercise of Warrant; Financial Statements. The Company will at all times reserve and keep available,
solely for issuance and delivery on the exercise of the Warrants, all shares of Common Stock (or Other Securities) from time to
time issuable on the exercise of the Warrant.

 

5.Assignment; Exchange
of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred
by any registered holder hereof (a “Transferor”). On the surrender for exchange of this Warrant, with the Transferor’s
endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”) and together with an
opinion of counsel reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance with applicable
securities laws, the Company at its expense, twice, only, but with payment by the Transferor of any applicable transfer taxes,
will issue and deliver to or on the order of the Transferor thereof a new Warrant or Warrants of like tenor, in the name of the
Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a “Transferee”), calling in
the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the Warrant
so surrendered by the Transferor. No such transfers shall result in a public distribution of the Warrant.

 

6.Replacement of
Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security
reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation
of this Warrant, the Company at its expense, twice only, will execute and deliver, in lieu thereof, a new Warrant of like tenor.

 

    	5

    	 

    
 

7.Transfer on the
Company’s Books. Until this Warrant is transferred on the books of the Company, the Company may treat the registered
holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.

 

8.Notices. 
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in
writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified,
return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted
by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed
effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine,
at the address or number designated below (if delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered other than on a business day during normal business
hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service,
fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: (i) if to the Company to: 80 Liberty Ship Way, Suite 7, Sausalito CA 94965, and (ii) if to the Holder,
80 Liberty Ship Way, Suite 7, Sausalito CA 94965.

 

9.Miscellaneous.
This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought. This Warrant shall be construed and
enforced in accordance with and governed by the laws of California. Any dispute relating to this Warrant shall be adjudicated in
San Diego County in the State of California. The headings in this Warrant are for purposes of reference only, and shall not limit
or otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect
the validity or enforceability of any other provision.

 

10.No rights as
Stockholder. Until the Holder has exercised this Warrant, Holder shall have no rights as a stockholder of the Company in respect
to the Warrants until the Holder has exercise its rights to receive Warrant Shares.

  

 

[THIS SPACE INTENTIONALLY
LEFT BLANK]

 

    	6

    	 

    
 

IN WITNESS WHEREOF, the
Company has executed this Warrant as of the date first written above.

 

	 	
        MIMVI, Inc. 

         

         

         

        By:  _________________________________

        Name:

        Title:

        

	 	 	 

 

    	7

    	 

    
 

Exhibit A

 

FORM OF SUBSCRIPTION

(to be signed only on exercise of Warrant)

 

TO: MIMVI,
Inc.

 

The undersigned, pursuant to the provisions
set forth in the attached Warrant (No.____), hereby irrevocably elects to purchase (check applicable box):

 

___________ shares of the Common Stock
covered by such Warrant; or

 

___the maximum number of shares of
Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth in Section 2.

 

The undersigned herewith makes payment
of the full purchase price for such shares at the price per share provided for in such Warrant, which is $___________. Such payment
takes the form of (check applicable box or boxes):

 

___$__________ in lawful money of the United States (which
sum reflects the concession amount described in Section 14 of the Warrant; and/or

 

___the cancellation of such portion
of the attached Warrant as is exercisable for a total of _______ shares of Common Stock (using a Fair Market Value of $_______
per share for purposes of this calculation); and/or

 

___the cancellation of such number
of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 2, to exercise this Warrant
with respect to the maximum number of shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth
in Section 2.

 

The undersigned requests that the certificates
for such shares be issued in the name of, and delivered to _____________________________________________________ whose address
is _________________________________________________

______________________________________
.

 

The undersigned represents and warrants
that all offers and sales by the undersigned of the securities issuable upon exercise of the within Warrant shall be made pursuant
to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”), or pursuant
to an exemption from registration under the Securities Act.

 

	Dated:___________________	
        ______________________________________

        (Signature must conform to name of holder as specified on the
        face of the Warrant)

         

___________________________________________ 

        ___________________________________________

        (Address)

 

    	8

    	 

    

 

Exhibit B

 

 

FORM OF TRANSFEROR ENDORSEMENT

(To be signed only on transfer of Warrant)

 

For value received, the
undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the
right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of MIMVI, INC. to which
the within Warrant relates specified under the headings “Percentage Transferred” and “Number Transferred,”
respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on
the books of MIMVI, Inc. with full power of substitution in the premises.

 

	Transferees	Percentage Transferred	Number Transferred
	 	 	 
	 	 	 
	 	 	 

 

 

	
        Dated: ______________, ___________

         

         

        ______________________________________

        Signed in the presence of:

         

         

        (Name)

         

         

        ACCEPTED AND AGREED:

        [TRANSFEREE]

         

         

        ______________________________________ 

        (Name)

        
	
        ______________________________________

        (Signature must conform to name of holder as specified on the
        face of the warrant)

         

         

         

        ______________________________________

        ______________________________________

        (address)

         

         

        ______________________________________

______________________________________ 

        (address)

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]